Breakthrough Discovery: New Biomarker Reveals Path to Schizophrenia Treatment
Researchers at Northwestern University have identified a potential biomarker for schizophrenia, which could lead to novel treatments for cognitive symptoms. The study discovered reduced levels of the protein 'Cacna2d1' in schizophrenia patients, and a synthetic version, SEAD1, showed promise in reversing cognitive issues in animal models.
- Country:
- India
A groundbreaking study conducted by researchers at Northwestern University has revealed a new biomarker for schizophrenia, potentially paving the way for innovative treatment strategies. The research indicates that this biomarker could help address cognitive symptoms, which are often neglected by existing medications.
Schizophrenia, a mental disorder characterized by impaired perception and interpretation of reality, can involve symptoms like disorganized thinking. Current treatments target hallucinations and delusions but do little for cognitive deficits, creating significant societal integration challenges for affected individuals.
The researchers found that levels of the protein 'Cacna2d1' were lower in schizophrenia patients. A synthetic version, named 'SEAD1', was tested on mice and corrected abnormal brain activity. The study highlights the potential for diagnosing schizophrenia with biomarkers and tailoring treatment for responsive individuals.
Google News